Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-08-07
Schrodinger, Inc.
Schrödinger sells computational chemistry and molecular discovery software to pharma, biotech, industrial, and academic customers and also monetizes collaborative and proprietary drug programs built on the same platform.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Depth Over Drug Heroics
The upside case is a cleaner hosted software business with deeper workflow control, not a single binary clinical surprise. The next real proof point is whether the new AI layer changes renewals, usage, and pricing power.

Analysis

Thesis
Schrödinger’s best 5-year path is not a single drug win but a business-model upgrade: if hosted delivery, Bunsen, and workflow-linked pricing turn its simulation stack into a deeper operating layer for discovery teams, AI-driven growth in molecular design throughput can convert into better revenue quality, faster software expansion, and a higher equity value.
Last Economy Alignment
AI and cheaper compute should expand in silico discovery demand, and Schrödinger owns real workflow and simulation control points. It is positive, not pivotal, because pharma internal stacks and generic agents can still dilute value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.2x (from 5 most recent analyses)
Reasoning
The upside case is a cleaner, stickier software story rather than a biotech moonshot. If hosted contracts make revenue more recurring, Bunsen lifts paid workflow depth, and some pricing shifts from licenses toward program and usage value, Schrödinger can grow faster than the underlying software market without needing a single binary clinical win. That supports a solid multi-year rerating path, but not an unconstrained hypergrowth one.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is value capture, not scientific relevance. Schrödinger likely stays useful, but the equity case weakens if hosted delivery only changes accounting, if Bunsen does not deepen renewals or spend, or if customers let internal stacks and generic agents sit between Schrödinger and the scientist. The good news is capital risk is manageable near term, especially after the Ajax cash inflow, so execution has time to work.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
They sit inside molecular discovery workflows, so cheaper AI and compute should send more research through their software. But they do not own the core compute bottleneck, and if big pharma or generic agents bypass their workspace, the value they keep shrinks.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.57
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case